Why It Matters
The crop protection industry faces simultaneous threats to manufacturer liability protections and individual pesticide products, countered by recent regulatory tailwinds from the EPA and mixed signals from the Trump administration. Senator Cory Booker’s Pesticide Injury Accountability Act would allow lawsuits against manufacturers even for EPA-approved products, while bills like H.R. 5196 target specific pesticides like diquat for outright bans.
CropLife America’s strategy combines aggressive opposition to liability expansion with offensive advocacy for regulatory frameworks favoring innovation—evident in its endorsement of the Plant Biostimulant Act and support for the USDA CROP Act, which would coordinate EPA-USDA approval processes.
By the Numbers
CropLife America spent $1,053,903 on in-house lobbying in the final quarter of 2025, marking a dramatic escalation from $329,765 in the first quarter. (https://app.legis1.com/lda-filings/detail?id=1963742#summary), $507,113 in the second quarter 2025 (https://app.legis1.com/lda-filings/detail?id=1991079#summary), and $728,238 in the third quarter 2025 (https://app.legis1.com/lda-filings/detail?id=2027586#summary).
The organization has spent approximately $52.5 million on federal advocacy since 2003, with $44.1 million through in-house efforts. The final quarter filing represents direct lobbying by CropLife’s internal team including Jay Ivey, Alexandra Dunn, and Molly S. O’Connor.
The group has also engaged external firms including Cornerstone Government Affairs Inc. and FGS Global (US) LLC for targeted legislative outreach.
The Agenda
CropLife America is actively opposing H.R.5196, which would ban diquat pesticide, and H.R.6066, restricting workers under 18 from handling pesticides. The organization is fighting expanded manufacturer liability proposals that would expose companies to litigation regardless of EPA compliance.
On offense, CropLife is pushing S.1999 to formalize EPA-USDA coordination on pesticide registrations with economic impact analyses. The group endorsed the bipartisan Plant Biostimulant Act to create federal regulatory clarity for emerging agricultural technologies.
The organization is also engaging on FIFRA, the Endangered Species Act, and EPA appropriations—reflecting intensified efforts as Congress addresses competing priorities within a polarized legislative environment.
Broader Context
Congressional hearings reflected deep ideological divisions in late 2025. Senate Environment and Public Works Committee hearings examined chemical safety, while House Agriculture Committee hearings highlighted calls for streamlined EPA approvals. Industry supporters like Senator Deb Fischer praised EPA backlog reductions, while critics raised safety concerns.
The Trump administration’s Make America Healthy Again Commission largely sidestepped aggressive pesticide restrictions, recommending studies instead of immediate action—providing significant relief for industry advocates who initially faced uncertainty about the commission’s direction.
Between The Lines
Democratic members pushed legislation threatening industry profits, including Booker’s liability expansion and the diquat ban, while Republican-controlled committees emphasized regulatory efficiency. The bipartisan USDA CROP Act gained traction, addressing industry complaints about regulatory delays.
Competitive Landscape
CropLife operates within an intensely competitive environment. Corteva Agriscience LLC, a major member company, spent $1,360,000 in first quarter of 2025 and $900,000 in the second quarter 2025 on nearly identical issues, demonstrating coordinated industry-wide effort.
The industry faces formidable opposition from environmental and labor advocates supporting Booker’s accountability act and farmworker protection measures. Congressional polarization reinforces competitive pressure across both offensive and defensive fronts.
The Bottom Line
CropLife America’s $1.05 million final quarter surge reflects an industry under simultaneous attack and advantage. The spending increase—up 220% from the first quarter —signals intensifying battles as Democrats push restrictions and Republicans defend agricultural productivity. With industry-wide coordination evident through member company spending, the outcome will determine whether manufacturers can consolidate recent EPA victories while preventing legislative backlash.
Access the Legis1 platform for comprehensive political news, data, and insights.
Spot something wrong? Report an issue with this article